Your browser doesn't support javascript.
loading
Physical performance and plasma metabolic profile as potential prognostic factors in metastatic lung cancer patients.
das Neves, Willian; Alves, Christiano R R; Dos Santos, Gabriela; Alves, Maria-Janieire N N; Deik, Amy; Pierce, Kerry; Dennis, Courtney; Buckley, Lily; Clish, Clary B; Swoboda, Kathryn J; Brum, Patricia C; de Castro Junior, Gilberto.
Afiliação
  • das Neves W; Faculdade de Medicina, Instituto do Cancer do Estado de Sao Paulo ICESP, Hospital das Clínicas HCFMUSP, Universidade de Sao Paulo, Sao Paulo, Brazil.
  • Alves CRR; Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Dos Santos G; Department of Neurology, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Alves MNN; Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Deik A; Department of Neurology, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Pierce K; School of Physical Education and Sport, University of São Paulo, São Paulo, Brazil.
  • Dennis C; Faculdade de Medicina, Instituto do Cancer do Estado de Sao Paulo ICESP, Hospital das Clínicas HCFMUSP, Universidade de Sao Paulo, Sao Paulo, Brazil.
  • Buckley L; Heart Institute, School of Medicine, University of Sao Paulo, Sao Paulo, Brazil.
  • Clish CB; Metabolomics Platform, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
  • Swoboda KJ; Metabolomics Platform, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
  • Brum PC; Metabolomics Platform, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
  • de Castro Junior G; Metabolomics Platform, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Eur J Clin Invest ; : e14288, 2024 Jul 26.
Article em En | MEDLINE | ID: mdl-39058257
ABSTRACT

BACKGROUND:

Low physical performance is associated with higher mortality rate in multiple pathological conditions. Here, we aimed to determine whether body composition and physical performance could be prognostic factors in non-small cell lung cancer (NSCLC) patients. Moreover, we performed an exploratory approach to determine whether plasma samples from NSCLC patients could directly affect metabolic and structural phenotypes in primary muscle cells.

METHODS:

This prospective cohort study included 55 metastatic NSCLC patients and seven age-matched control subjects. Assessments included physical performance, body composition, quality of life and overall survival rate. Plasma samples from a sub cohort of 18 patients were collected for exploratory studies in cell culture and metabolomic analysis.

RESULTS:

We observed a higher survival rate in NSCLC patients with high performance in the timed up-and-go (+320%; p = .007), sit-to-stand (+256%; p = .01) and six-minute walking (+323%; p = .002) tests when compared to NSCLC patients with low physical performance. There was no significant association for similar analysis with body composition measurements (p > .05). Primary human myotubes incubated with plasma from NSCLC patients with low physical performance had impaired oxygen consumption rate (-54.2%; p < .0001) and cell proliferation (-44.9%; p = .007). An unbiased metabolomic analysis revealed a list of specific metabolites differentially expressed in the plasma of NSCLC patients with low physical performance.

CONCLUSION:

These novel findings indicate that physical performance is a prognostic factor for overall survival in NSCLC patients and provide novel insights into circulating factors that could impair skeletal muscle metabolism.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Eur J Clin Invest Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Brasil

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Eur J Clin Invest Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Brasil